Filing Flows › Zentalis Pharmaceuticals (ZNTL) › Q4 2024
Zentalis Pharmaceuticals (ZNTL) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 26, 2025
Zentalis Pharmaceuticals (ZNTL) reported revenue of $26.9M for the fourth quarter 2024 (Q4 2024). Operating margin was -185.6%, net loss $47.5M (176.7% of revenue).
Zentalis Pharmaceuticals, Q4 2024: revenue $26.9M, operating margin -185.6%, net loss $47.5M, operating cash flow −$39.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26.9M | — | — |
| Operating profit | −$49.8M | — | — |
| Net earnings | −$47.5M | — | — |
| Operating cash flow | −$39.7M | — | — |
What changed
Revenue was $26.9M in Q4 2024.
Operating costs exceeded revenue by $49.8M, an operating margin of -185.6%. The quarter ended with a net loss of $47.5M.
Operating cash flow was −$39.7M. Non-cash charges added back $317K of depreciation and amortization and $31.4M of share-based compensation. Working capital and other items used $23.9M.
Questions
What was Zentalis Pharmaceuticals' revenue in the fourth quarter 2024?
Zentalis Pharmaceuticals (ZNTL) reported revenue of $26.9M for the fourth quarter 2024 (Q4 2024).
Was Zentalis Pharmaceuticals profitable in the fourth quarter 2024?
Operating loss was $49.8M (-185.6% of revenue) and net loss $47.5M.